Delia D'Avola-rekin lankidetzan egindako argitalpenak (40)

2023

  1. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

2022

  1. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

2019

  1. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know

    CardioVascular and Interventional Radiology, Vol. 42, Núm. 9, pp. 1262-1270

2017

  1. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil

    Liver Transplantation, Vol. 23, Núm. 4, pp. 498-509

  2. Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation

    Annals of Transplantation, Vol. 22, pp. 141-147

  3. Immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

    Immunotherapy of Hepatocellular Carcinoma (Springer International Publishing), pp. 51-68

  4. Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma

    RESISTANCE TO MOLECULAR THERAPIES FOR HEPATOCELLULAR CARCINOMA (SPRINGER INTERNATIONAL PUBLISHING AG), pp. 25-43

  5. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma

    Oncotarget, Vol. 8, Núm. 25, pp. 40967-40981

  6. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Controlling Diabetes after Liver Transplantation: Room for Improvement

    Transplantation, Vol. 100, Núm. 10, pp. e66-e73

  2. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

  3. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 776-783

  4. Recombinant AAV Integration Is Not Associated with Hepatic Genotoxicity in Nonhuman Primates and Patients

    Molecular Therapy, Vol. 24, Núm. 6, pp. 1100-1105

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

  3. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma

    Liver International, Vol. 35, Núm. 6, pp. 1715-1721

  4. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

  5. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  2. Is liver biopsy necessary in the evaluation of a living donor for liver transplantation?

    Transplantation Proceedings